Biogen Inc.: Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Santé log

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

A Re-Emerging Portfolio Building Block: The Case For International Inflation-Linked Securities

International inflation linked securities are re-emerging as a compelling portfolio building block for US investors. Read ...